Pre-made Drozitumab biosimilar ( Whole mAb, anti-TNFRSF10B therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-156
Anti-TNFRSF10B therapeutic antibody (Pre-made Drozitumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFRSF10B therapeutic antibody (Pre-made Drozitumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||4od2:BA|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer|